Take a medication to continue managing your blood disorder long-term

Back to Myelodysplastic Syndromes (MDS) trials

What is this trial?

This is a follow-up study for patients who have already been participating in trials testing , a medication being developed to help people with certain blood disorders like myelodysplastic syndromes, beta-thalassemia, and myeloproliferative neoplasm-associated myelofibrosis. The study will track how safe and how well this medication continues to work over a long period of time—up to several years. Patients who were already taking the medication (or received a placebo) in an earlier trial can continue or switch to receive the treatment here.

Doctors need to understand how a new medication performs over the long term, especially whether it remains safe and continues to help patients over months and years. This study exists to gather that important safety information and to keep watch for any side effects that might develop with extended use of the treatment.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have already been participating in another luspatercept trial and tolerated the treatment well
you were assigned to receive luspatercept (or placebo that you can now switch from) in the original study
your doctor believes you are still benefiting from continuing this medication
you are willing to attend study visits on a regular schedule
if you are a woman who could become pregnant, you agree to use reliable contraception and have pregnancy tests during the study

You likely don't qualify if…

you have not participated in a previous luspatercept trial
you did not tolerate the medication well in the earlier study
you are unable to attend regular study visits and follow the study plan
you are a woman of childbearing potential who cannot or will not use reliable contraception during the study

What participation looks like

You will come to a clinic to receive injections of the medication under your skin, using the same dose and schedule you were already receiving in the previous trial. Your study visits will include one initial enrollment visit to transition into this study, then ongoing treatment visits. After your last dose, you'll have a 42-day safety check-up, and then you'll be contacted every 6 months for at least 3 to 5 years to check on your overall health, how you're doing, and whether any new health issues have developed.

Long-term Safety Study for Blood Disorder Patients Continuing Treatment

What is this trial?

Do you qualify?

What participation looks like

Trial locations(143 sites)